Himabindu Peddapalli, G. V Radha
Himabindu Peddapalli1*, G. V Radha2
1Department of Pharmaceutics, School of Pharmacy, Anurag University, Ghatkesar, Telangana, India – 500088.
2Department of Pharmaceutics, Gitam Institute of Pharmacy, Gitam University, Visakhapatnam, Andhra Pradesh, India – 530045.
Volume - 15,
Issue - 3,
Year - 2022
The sublingual and buccal routes of administration have significant advantages for both local and systemic drug delivery. They have shown to be an effective alternative to the traditional oral route, especially when fast onset of action is required. Drugs can be rapidly and directly absorbed into the systemic circulation via venous drainage to the superior vena cava The buccal route is considered patient friendly due to its non-invasive nature and ease of administration. Such delivery route has been used as an alternative for the delivery of drugs that undergo first-pass metabolism or are susceptible to pH and enzymatic degradation, such as occurs in the gastrointestinal tract. However, the drug concentration absorbed in the buccal mucosa is often low to obtain an acceptable therapeutic effect, mainly due to the saliva turnover, tongue and masticatory movements, phonation, enzymatic degradation and lack of epithelium permeation. Therefore, the encapsulation of drugs into nanoparticles is an important strategy to avoid such problems and improve their buccal delivery. Different materials from lipids to natural or synthetic polymers and others have been used to protect and deliver drugs in a sustained, controlled or targeted manner, and enhance their uptake through the buccal mucosa improving their bioavailability and therapeutic outcome. Overall, the main aim of this review is to perform an overview about the nanotechnological approaches developed so far to improve the buccal delivery of drugs. Herein, several types of nanoparticles and delivery strategies are addressed, and a special focus on pipeline products is also given.
Cite this article:
Himabindu Peddapalli, G. V Radha. Current approaches in Lipidic-nanoparticle Systems for Buccal Drug Delivery. Research Journal of Pharmacy and Technology. 2022; 15(3):1353-8. doi: 10.52711/0974-360X.2022.00226
Himabindu Peddapalli, G. V Radha. Current approaches in Lipidic-nanoparticle Systems for Buccal Drug Delivery. Research Journal of Pharmacy and Technology. 2022; 15(3):1353-8. doi: 10.52711/0974-360X.2022.00226 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-3-69
1. Jager, J., Obst, K, Characterization of hyperbranched core‐multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa. Journal of Periodontal Research, (2015 ), 53(1), pp.57-65.
2. Singh, A.P., Biswas, A., Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduction and Targeted Therapy,(2019) 4(1), pp.1-21.
3. Chung, W.O. and Dommisch, H., Antimicrobial peptides of skin and oral mucosa. Innate Immune System of Skin and Oral Mucosa: Properties and Impact in Pharmaceutics, Cosmetics, and Personal Care Products, John Wiley and Sons, (2011)pp.117-144.
4. N. Langoth, J. Kalbe, A. Bernkop-Schnurch, Development of buccal drug delivery systems based on a thiolated polymer, Int. J. Pharm. 2003, pp 141–148.
5. Mohanty, D., Rani, M.J., Haque, Preparation and evaluation of transdermal naproxen niosomes: formulation optimization to preclinical anti-inflammatory assessment on murine model. Journal of Liposome Research, (2019; pp.1-11.
6. J.O. Morales, J.T. McConville, Novel strategies for the buccal delivery of macromolecules, Drug Dev. Ind. Pharm. 40 (2014) 579–590.
7. A. Patel, M. Patel, X. Yang, A.K. Mitra, Recent advances in protein and peptide drug delivery: A special emphasis on polymeric nanoparticles, Protein Pept. Lett. 21 (2014) 1102–1120.
8. M. Ochubiojo, I. Chinwude, E. Ibanga, Nanotechnology in drug delivery, Recent Advances in Novel Drug Carrier Systems, Intech Open, London, 2012, pp. 69–106.
9. F. Sousa, P. Castro, P. Fonte, B. Sarmento, How to overcome the limitations of current insulin administration with new non-invasive delivery systems, Drug. Delivery. 6 (2015) 83–94.
10. P. Fonte, F. Araújo, S. Reis, B. Sarmento, Oral insulin delivery: how far are we? JDST 7 (2013) 520–531.
11. D. Harris, J.R. Robinson, Drug delivery via the mucous membranes of the oral cavity, J. Pharm. Sci. 81 (1992) 1–10.
12. M.J. Rathbone, B.K. Drummond, I.G. Tucker, The oral cavity as a site for systemic drug delivery, Adv. Drug Deliv. Rev. 13 (1994) 1–22.
13. N. Hassan, A. Ahad, M. Ali, J. Ali, Chemical permeation enhancers for transbuccal drug delivery, Expert Opin Drug Deliv 7 (2010) 97–112.
14. G. Campisi, C. Paderni, R. Saccone Human buccal mucosa as an innovative site of drug delivery, Curr. Pharm. Des. 16 (2010) 641–652. [
15. A.H. Shojaei, Buccal mucosa as a route for systemic drug delivery: a review, J. Pharm.Pharm. Sci. 1 (1998) 15–30.
16. Mohanty D, Jhansi M, Upadhyay AK. Niosomes: A Novel Trend in Drug Delivery. Research Journal of Pharmacy and Technology. 2018;11(11):5205-11.
17. M.J. Rathbone, I.G. Tucker, Mechanisms, barriers and pathways of oral mucosal drug permeation, Adv. Drug Deliv. Rev. 12 (1993) 41–60.  J. Chen, R. Ahmad, W. Li, M. Swain, Q. Li, Biomechanics of oral mucosa, J. R. Soc. Interface 12 (2015) 1–15.
18. D.J. Aframian, T. Davidowitz, R. Benoliel, The distribution of oral mucosal pH values in healthy saliva secretors, Oral Dis. 12 (2006) 420–423.
19. S. Cornick, A. Tawiah, K. Chadee, Roles and regulation of the mucus barrier in the gut, Tissue Barriers 3 (2015) 1–15
20. Yamamoto K, Klossek A, Flesch R, et al. Core-multishell nanocarriers: transport and release of dexamethasone probed by soft X-ray spectromicroscopy. J Control Release. 2016;242:64-70.
21. Pramod Salve, Suvarna Pise, Nikhil Bali. Formulation and Evaluation of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System for Alzheimer’s Disease. Res. J. Pharm. Dosage Form. and Tech. 2016; 8(2):73-80.
22. D. Krishna Veni, N. Vishal Gupta. Quality by Design approach in the development of Solid Lipid Nanoparticles of Linagliptin. Research J. Pharm. and Tech 2019; 12(9):4454-4462.
23. Rohan R. Vakhariya, Swati S. Talokar, V. R. Salunkhe, C. S. Magdum. Formulation Development and Optimization of Simvastatin Loaded Solid Lipid Nanoparticles. Asian J. Res. Pharm. Sci. 2017; 7(1): 49-52
24. S. D. Mankar, Anjali Dama, M. S. Bhosale, Dr. S. S. Sidhheshwar. Design, Development, Characterization of Solid Lipid Nanoparticles for Oral Administration. Research J. Science and Tech. 2020; 12(1):79-95.
25. Manjunath Kopparam, Suresh V Kulkarni, Shivu SN. Development, Characterization and In vitro Evaluation of Donepezil solid Lipid Nanoparticles. Research J. Pharm. and Tech. 2020; 13(7): 3113-3121
26. Kumar S, Alnasif N, Fleige E, et al. Impact of structural differences in hyperbranched polyglycerol-polyethylene glycol nanoparticles on dermal drug delivery and biocompatibility. Eur J Pharm Biopharm. 2014;88:625-634.
27. Saeidpour S, Lohan SB, Anske M, et al. Localization of dexamethasone within dendritic core-multishell (CMS) nanoparticles and skin penetration properties studied by multi-frequency electron paramagnetic resonance spectroscopy (EPR). Eur J Pharm Biopharm 2016;116:94-101.
28. Jameel Ahmed Mulla, Sarasija Suresh, Imtiyaz Ahmed Khazi. Formulation, Characterization and in vitro Evaluation of Methotrexate Solid Lipid Nanoparticles. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page 685-689.
29. Amol S. Deshmukh. Solid Lipid Nanoparticles. Res. J. Pharm. Dosage Form. and Tech. 6(4):Oct.- Dec.2014; Page 282-285
30. Akshat Sharma, Amit Dubey, Reenu Yadav,Solid Lipid Nanoparticles: A Promising Nanotechnology. Research J. Pharma. Dosage Forms and Tech. 2011; 3(5): 167-175 .
31. Trilochan Satapathy, Prasanna Kumar Panda. Solid Lipid Nanoparticles: A Novel Carrier in Drug Delivery System. Research J. Pharma. Dosage Forms and Tech. 2013; 5(2): 56-61 .